Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Weight loss drugs Ozempic and Wegovy would no longer be covered by California's health insurance for low-income people under ...

PEOPLE regain the weight they lose on fat jabs within two years of stopping the drugs, research suggests. Ozempic-style injections like Wegovy and Mounjaro are a roaring success due to their rapid ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

California is not required by federal law to cover the cost of the weight loss drugs in its Medi-Cal program. Instead, the state opted to include them. Under Newsom’s proposed cuts, when Ozempic is ...

The analysis of 11 weight-loss drug studies by the University of Oxford found that patients typically lost 8kg (18lb) after ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.